Abstract:The cannabinoid system has been demonstrated to modulate the acute and chronic pain of multiple origins. Mouse VD-hemopressin (alpha) [(m)VD-Hp alpha], an 11-residue a-hemoglobin-derived peptide, was recently reported to function as a selective agonist of the cannabinoid receptor type 1 (CB1) in vitro. To characterize its behavioral and physiological properties, we investigated the in vivo effects of (m) VD-Hpa in mice. In the mouse tail-flick test, (m)VD-Hp alpha dose-dependently induced antinociception after supraspinal (EC50 = 6.69 nmol) and spinal (EC50 = 2.88 nmol) administration. The antinociceptive effects of (m)VD-Hp alpha (intracerebroventricularly and intrathecally) were completely blocked by N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)4- methyl-1H-pyrazole-3-carboxamide (AM251; CB1 antagonist), but not by 6-iodo-2-methyl-1-[ 2-(4-morpholinyl) ethyl]-1H-indol-3-yl (4-methoxyphenyl)-methanone (AM630; CB2 antagonist) or naloxone (opioid antagonist), showing its selectivity to the CB1 receptor. Furthermore, the central nervous system (CNS) effects of (m)VD-Hp alpha were evaluated in body temperature, locomotor activity, tolerance development, reward, and food intake assays. At the highly antinociceptive dose (3 x EC50), (m)VD-Hp alpha markedly exerted hypothermia and hypoactivity after supraspinal administration. Repeated intracerebroventricular injection of (m)VD-Hp alpha resulted in both development of tolerance to antinociception and conditioned place aversion. In addition, central injection of (m)VD-Hp alpha dose-dependently stimulated food consumption. These findings demonstrate that this novel cannabinoid peptide agonist induces CB1-mediated central antinociception with some CNS effects, which further supports a CB1 agonist character of (m)VD-Hp alpha. Moreover, the current study will be helpful to understand the in vivo properties of the endogenous peptide agonist of the cannabinoid CB1 receptor.

Antinociceptive Effects of Central Administration of the Endogenous Cannabinoid Receptor Type 1 Agonist VDPVNFKLLSH-OH [(M)vd-Hemopressin(α)], an N-terminally Extended Hemopressin Peptide.